Ranbaxy Rules Out "At-Risk" Lipitor Launch: Report
Indian generic maker Ranbaxy Laboratories Ltd. won't launch a generic version of Pfizer Inc.'s best-selling anti-cholesterol drug Lipitor "at risk" if it wins its patent challenge at the district-court level, according...To view the full article, register now.
Already a subscriber? Click here to view full article